Neha Vapiwala, MD, on Prostate Cancer: Imaging and the Decision to Treat With Radiation
2020 ASTRO Annual Meeting
Neha Vapiwala, MD, of the University of Pennsylvania, who served as a discussant for LBA1, summarizes her review of this study of patients with prostate cancer who had biochemical recurrence in the post-prostatectomy setting, who were candidates for salvage radiotherapy, and who received either conventional imaging or PET scans to help determine the course of treatment.
The ASCO Post Staff
Daniel E. Spratt, MD, of the University of Michigan Rogel Cancer Center, discusses phase III results of the HERO trial, which suggested benefits of the oral medication relugolix: a substantially faster time to castration with longer duration, fewer cardiac events, and a faster return to normal testosterone levels compared with leuroplide (Abstract 35).
The ASCO Post Staff
Paul Sargos, MD, of the Institut Bergonié, discusses phase III findings from the GETUG-AFU 17 study, which compared adjuvant vs early salvage radiotherapy, both combined with short-term androgen-deprivation therapy after radical prostatectomy for localized prostate cancer. Although lacking statistical power, the study showed no benefit in event-free survival for adjuvant compared to salvage radiotherapy (Abstract 33).
Juliane Hörner-Rieber, MD, of Heidelberg University Hospital, discusses phase III results of the MINT trial, which showed that conventionally fractionated intensity-modulated radiotherapy with a simultaneous integrated boost was noninferior to three-dimensional conformal radiotherapy followed by a sequential boost for both local control and cosmesis in patients with breast cancer (Abstract 19).
The ASCO Post Staff
Youssef Zeidan, MD, PhD, of the American University of Beirut Medical Center, discusses study findings showing that breast-conserving surgery, whole-breast irradiation, and trastuzumab offer effective local tumor control for patients with HER2-positive breast cancer. An additional radiation boost does not seem to further improve outcomes (Abstract 52).
Daniel E. Spratt, MD, of the University of Michigan Rogel Cancer Center, discusses a pooled analysis of two phase III trials showing adjuvant androgen-deprivation therapy (ADT) improves biochemical control and reduces distant metastasis when compared with a neoadjuvant approach, with no difference in late gastrointestinal or genitourinary toxicities. The analysis also showed that delaying radiotherapy to deliver neoadjuvant ADT did not benefit most patients (Abstract 32).
